Bioventix plc
("Bioventix" or the "Company")
Director/PDMR Shareholding
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 31 March 2023 of the following transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):
| Director | Role | Ordinary Shares sold | Average sale price per Ordinary Share | Ordinary Shares subsequently held | Percentage of issued share capital subsequently held |
| Ian Nicholson and Persons Closely Associated | Non-Executive Chairman | 2,500 | 3,900 | 13,000 | 0.2% |
The notifications below, which have been made in accordance with the requirements of the Market Abuse Regulation, provide further details.
For further information please contact:
| Bioventix plc Peter Harrison Bruce Hiscock |
Chief Executive Officer Chief Financial Officer | Tel: 01252 728 001 |
| | | |
| finnCap Ltd Geoff Nash/Simon Hicks Alice Lane |
Corporate Finance ECM | Tel: 020 7220 0500 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA") | |||||
| a) | Name | Ian Nicholson | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chairman | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Bioventix plc | ||||
| b) | LEI | 213800225MHX7LZQY108 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||||
| Identification code | GB00B4QVDF07 | |||||
| b) | Nature of the transaction | Sale of Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | See 4(c) | ||||
| e) | Date of the transaction | 31 March 2023 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
| 1 | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA") | |||||
| a) | Name | Catherine Nicholson | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | PCA of Ian Nicholson, Chairman | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Bioventix plc | ||||
| b) | LEI | 213800225MHX7LZQY108 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 5 pence each | ||||
| Identification code | GB00B4QVDF07 | |||||
| b) | Nature of the transaction | Sale of Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | See 4(c) | ||||
| e) | Date of the transaction | 31 March 2023 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.